Multicenter evaluation of three commercial methods for measuring protein S antigen

A. Tripodi, R. M. Bertina, J. Conard, I. Pabinger, N. Sala, P. M. Mannucci

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

This collaborative study was designed to assess the performance of commercial methods for protein S (PS) antigen measurement. Twenty-five different samples were distributed deep-frozen (24 plasmas) or lyophilized (one plasma) to five laboratories. They were analyzed blind in each laboratory by the method used locally and by three commercial methods which included two electroimmunoassays (EIA), Asseraplate-PS (Diagnostica Stago), Rellplate-S (American Diagnostica) and an ELISA system, Asserachrom-PS (Diagnostica Stago). 1. Reproducibility. Average between-laboratory coefficients of variation were 15.4%, 17.6% and 25.3% for Asserachrom-PS, Asseraplate-PS and Rellplate-S. 2. Specificity. Results of all methods showed that PS is underestimated when C4b binding protein is high. This influence was particularly evident for the ELISA Asserachrom-PS and disappeared when the antibody-antigen incubation period was prolonged to overnight. 3. Sensitivity. In all laboratories ELISA detected even the lowest PS concentration (4U/dl), whereas the two EIAs were less sensitive (lower detection limit 14U/dl). All methods and laboratories correctly diagnosed a plasma sample from a PS congenitally deficient patient. Conclusions. This study shows that better standardization of PS immunoassays is necessary to improve accuracy and reduce interlaboratory variability before a candidate plasma standard can be successfully calibrated in an international collaborative study.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalThrombosis and Haemostasis
Volume68
Issue number2
Publication statusPublished - 1992

Fingerprint

Protein S
Antigens
Enzyme-Linked Immunosorbent Assay
Complement C4b-Binding Protein
Immunoassay
Limit of Detection
Antibodies

ASJC Scopus subject areas

  • Hematology

Cite this

Multicenter evaluation of three commercial methods for measuring protein S antigen. / Tripodi, A.; Bertina, R. M.; Conard, J.; Pabinger, I.; Sala, N.; Mannucci, P. M.

In: Thrombosis and Haemostasis, Vol. 68, No. 2, 1992, p. 149-154.

Research output: Contribution to journalArticle

Tripodi, A. ; Bertina, R. M. ; Conard, J. ; Pabinger, I. ; Sala, N. ; Mannucci, P. M. / Multicenter evaluation of three commercial methods for measuring protein S antigen. In: Thrombosis and Haemostasis. 1992 ; Vol. 68, No. 2. pp. 149-154.
@article{9480abf0db324d56ad3186889aec405e,
title = "Multicenter evaluation of three commercial methods for measuring protein S antigen",
abstract = "This collaborative study was designed to assess the performance of commercial methods for protein S (PS) antigen measurement. Twenty-five different samples were distributed deep-frozen (24 plasmas) or lyophilized (one plasma) to five laboratories. They were analyzed blind in each laboratory by the method used locally and by three commercial methods which included two electroimmunoassays (EIA), Asseraplate-PS (Diagnostica Stago), Rellplate-S (American Diagnostica) and an ELISA system, Asserachrom-PS (Diagnostica Stago). 1. Reproducibility. Average between-laboratory coefficients of variation were 15.4{\%}, 17.6{\%} and 25.3{\%} for Asserachrom-PS, Asseraplate-PS and Rellplate-S. 2. Specificity. Results of all methods showed that PS is underestimated when C4b binding protein is high. This influence was particularly evident for the ELISA Asserachrom-PS and disappeared when the antibody-antigen incubation period was prolonged to overnight. 3. Sensitivity. In all laboratories ELISA detected even the lowest PS concentration (4U/dl), whereas the two EIAs were less sensitive (lower detection limit 14U/dl). All methods and laboratories correctly diagnosed a plasma sample from a PS congenitally deficient patient. Conclusions. This study shows that better standardization of PS immunoassays is necessary to improve accuracy and reduce interlaboratory variability before a candidate plasma standard can be successfully calibrated in an international collaborative study.",
author = "A. Tripodi and Bertina, {R. M.} and J. Conard and I. Pabinger and N. Sala and Mannucci, {P. M.}",
year = "1992",
language = "English",
volume = "68",
pages = "149--154",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Multicenter evaluation of three commercial methods for measuring protein S antigen

AU - Tripodi, A.

AU - Bertina, R. M.

AU - Conard, J.

AU - Pabinger, I.

AU - Sala, N.

AU - Mannucci, P. M.

PY - 1992

Y1 - 1992

N2 - This collaborative study was designed to assess the performance of commercial methods for protein S (PS) antigen measurement. Twenty-five different samples were distributed deep-frozen (24 plasmas) or lyophilized (one plasma) to five laboratories. They were analyzed blind in each laboratory by the method used locally and by three commercial methods which included two electroimmunoassays (EIA), Asseraplate-PS (Diagnostica Stago), Rellplate-S (American Diagnostica) and an ELISA system, Asserachrom-PS (Diagnostica Stago). 1. Reproducibility. Average between-laboratory coefficients of variation were 15.4%, 17.6% and 25.3% for Asserachrom-PS, Asseraplate-PS and Rellplate-S. 2. Specificity. Results of all methods showed that PS is underestimated when C4b binding protein is high. This influence was particularly evident for the ELISA Asserachrom-PS and disappeared when the antibody-antigen incubation period was prolonged to overnight. 3. Sensitivity. In all laboratories ELISA detected even the lowest PS concentration (4U/dl), whereas the two EIAs were less sensitive (lower detection limit 14U/dl). All methods and laboratories correctly diagnosed a plasma sample from a PS congenitally deficient patient. Conclusions. This study shows that better standardization of PS immunoassays is necessary to improve accuracy and reduce interlaboratory variability before a candidate plasma standard can be successfully calibrated in an international collaborative study.

AB - This collaborative study was designed to assess the performance of commercial methods for protein S (PS) antigen measurement. Twenty-five different samples were distributed deep-frozen (24 plasmas) or lyophilized (one plasma) to five laboratories. They were analyzed blind in each laboratory by the method used locally and by three commercial methods which included two electroimmunoassays (EIA), Asseraplate-PS (Diagnostica Stago), Rellplate-S (American Diagnostica) and an ELISA system, Asserachrom-PS (Diagnostica Stago). 1. Reproducibility. Average between-laboratory coefficients of variation were 15.4%, 17.6% and 25.3% for Asserachrom-PS, Asseraplate-PS and Rellplate-S. 2. Specificity. Results of all methods showed that PS is underestimated when C4b binding protein is high. This influence was particularly evident for the ELISA Asserachrom-PS and disappeared when the antibody-antigen incubation period was prolonged to overnight. 3. Sensitivity. In all laboratories ELISA detected even the lowest PS concentration (4U/dl), whereas the two EIAs were less sensitive (lower detection limit 14U/dl). All methods and laboratories correctly diagnosed a plasma sample from a PS congenitally deficient patient. Conclusions. This study shows that better standardization of PS immunoassays is necessary to improve accuracy and reduce interlaboratory variability before a candidate plasma standard can be successfully calibrated in an international collaborative study.

UR - http://www.scopus.com/inward/record.url?scp=0026629754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026629754&partnerID=8YFLogxK

M3 - Article

C2 - 1412159

AN - SCOPUS:0026629754

VL - 68

SP - 149

EP - 154

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -